Oral Rivaroxaban for Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [88]
Citations
Cites
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, G. D., Claessen, B. E., Caixeta, A., Sanidas, E. A., Mintz, G. S., & Mehran, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.07.028 · Cited by 803
Incidence of Venous Thromboembolism: A Community-based Study in Western France
Oger, E., & the EPI-GETBO Study Group (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613887 · Cited by 711
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Rodger, M. A., Kahn, S. R., Wells, P. S., Anderson, D. A., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M., Perrier, A., White, R., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080493 · Cited by 581
Research works printed but not linked: 1
- Hutten BA, 2006, Cochrane Database Syst Rev, 1, CD001367
Cited by
Items 501–600 of 1,010
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
Cross, B., Turner, R. M., Zhang, E. J., & Pirmohamed, M. (2024) · The Pharmacogenomics Journal · doi:10.1038/s41397-024-00329-y · Cited by 48
Basics of diagnosis and treatment of venous thromboembolism
Cox, C., & Roberts, L. N. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.01.009 · Cited by 50
A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism
Kearon, C. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04629.x · Cited by 45
The in vitro anticoagulant effect of rivaroxaban in children
Attard, C., Monagle, P., Kubitza, D., & Ignjatović, V. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.07.009 · Cited by 45
On behalf of the PREFER in VTE investigators, Agnelli, G., Gitt, A. K., Bauersachs, R. M., Fronk, E., Laeis, P., Mismetti, P., Monréal, M., Willich, S. N., Wolf, W.-P., et al. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0071-z · Cited by 47
Bookhart, B., Haskell, L. P., Bamber, L., Wang, M., Schein, J. R., & Mody, S. H. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.946993 · Cited by 45
Is it time for home treatment of pulmonary embolism?
Lankeit, M., & Konstantinides, S. (2012) · European Respiratory Journal · doi:10.1183/09031936.00216811 · Cited by 45
Douxfils, J., Tamigniau, A., Châtelain, B., Goffinet, C., Dogné, J.-M., & Mullier, F. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-24 · Cited by 53
“Effectively, they were found at least as efficacious, if not better, than warfarin in the setting of stroke prevention in adult patients with non-valvular atrial fibrillation (NVAF) [1-4] and in the treatment and the secondary prevention of venous thromboembolism [5-9].”
BackgroundEvidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
Aronis, K. N., & Hylek, E. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007338 · Cited by 48
Pharmacological reversal of the direct oral anticoagulants—A comprehensive review of the literature
Shaw, J. R., & Siegal, D. M. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12089 · Cited by 47
Soares, R. D. A., Matielo, M. F., Neto, F. C. B., Nogueira, M. P., de Almeida, R. D., & Sacilotto, R. (2019) · Surgery · doi:10.1016/j.surg.2019.05.030 · Cited by 47
Houghton, D. E., Vlazny, D. T., Casanegra, A. I., Brunton, N. E., Froehling, D. A., Meverden, R. A., Hodge, D. O., Peterson, L. G., McBane, R. D., & Wysokiński, W. E. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.026 · Cited by 46
“in the treatment and secondary prevention of venous thromboembolism (VTE) (1-6) but since patients with cancer-associated VTE (Ca-VTE) are at increased risk for both recurrent VTE and bleeding new studies specifically designated for Ca-VTE were necessary.”
BackgroundKang, N., & Sobieraj, D. M. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.03.035 · Cited by 52
Lozano, F. S., Trujillo‐Santos, J., Barrón, M., Gallego, P., Babalis, D., Santos, M., Falgà-Tirado, C., & Monréal, M. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.11.091 · Cited by 44
Prandoni, P. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01733.x · Cited by 44
Sindet-Pedersen, C., Pallisgaard, J. L., Staerk, L., Berger, J. S., Lamberts, M., Torp-Pedersen, C., Gislason, G. H., & Olesen, J. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-03596-x · Cited by 44
Bunz, T. J., Turpie, A. G. G., & Coleman, C. I. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0210 · Cited by 46
Eerenberg, E. S., Cohen, A. T., Middeldorp, S., Raskob, G. E., Buller, H. R., Bleker, S. M., & Brekelmans, M. P. A. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0946 · Cited by 47
Goggs, R. A. N., Bacek, L. M., Bianco, D., Koenigshof, A. M., & Li, R. H. L. (2019) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12791 · Cited by 50
Sex matters: Practice 5P's when treating young women with venous thromboembolism
Bistervels, I. M., Scheres, L. J. J., Hamulyák, E. N., & Middeldorp, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14549 · Cited by 48
Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus
Willeford, A., Zhu, W., Stevens, C., & Thomas, I. C. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020975111 · Cited by 46
Apixaban and rivaroxaban in patients with acute venous thromboembolism
Bott-Kitslaar, D. M., McBane, R. D., Casanegra, A. I., Houghton, D. E., Froehling, D. A., Vlazny, D. T., Ashrani, A. A., Hodge, D. O., Vargas, E. R., Bartlett, M. A., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.09.022 · Cited by 43
A rapid pro-hemostatic approach to overcome direct oral anticoagulants
Thalji, N. K., Ivanciu, L., Davidson, R., Gimotty, P. A., Krishnaswamy, S., & Camire, R. M. (2016) · Nature Medicine · doi:10.1038/nm.4149 · Cited by 43
Belley‐Côté, E. P., Hanif, H., D’Aragon, F., Eikelboom, J. W., Anderson, J. L., Borgman, M. P., Jonas, D. E., Kimmel, S., Manolopoulos, V. G., Baranova, E. V., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-01-0071 · Cited by 44
Cancer-Associated Thrombosis: Pathophysiology, Laboratory Assessment, and Current Guidelines
Tsantes, A. G., Petrou, E., Tsante, K. A., Sokou, R., Frantzeskaki, F. G., Domouchtsidou, A., Chaldoupis, A. E., Fortis, S. P., Piovani, D., Nikolopoulos, G. K., et al. (2024) · Cancers · doi:10.3390/cancers16112082 · Cited by 63
“High risk ( ≥ 3 points): prophylaxis indicated.”
Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants
Ageno, W., Caramelli, B., Donadini, M. P., Girardi, L., & Riva, N. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00281-3 · Cited by 56
Enoxaparin: a pharmacologic and clinical review
Iqbal, Z., & Cohen, M. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.570261 · Cited by 47
Antiphospholipid syndrome: an update
Merashli, M., Noureldine, M. H. A., Uthman, I. W., & Khamashta, M. A. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12449 · Cited by 47
Meta-Analysis of Rivaroxaban and Bleeding Risk
Wasserlauf, G., Grandi, S. M., Filion, K. B., & Eisenberg, M. J. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.03.054 · Cited by 46
Mega, J. L., Braunwald, E., Wiviott, S. D., Murphy, S. A., Plotnikov, A. N., Gotcheva, N. N., Ruda, M., & Gibson, C. M. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.04.011 · Cited by 44
Ageno, W., & Beyer‐Westendorf, J. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0484 · Cited by 46
Barco, S., Lankeit, M., Binder, H., Schellong, S., Christ, M., Beyer‐Westendorf, J., Duerschmied, D., Bauersachs, R. M., Empen, K., Held, M., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-01-0004 · Cited by 48
Gaertner, S., Cordeanu, E., Nouri, S., Faller, A., Frantz, A., Mirea, C., Bilbault, P., Ohlmann, P., Ray, I. L., & Stéphan, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.045 · Cited by 50
Current challenges and future prospects in oral anticoagulant therapy
Czuprynska, J., Patel, J. P., & Arya, R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14714 · Cited by 45
“Patients with a CrCl below 30 ml/ min were excluded from the acute DVT and continued treatment studies (Bauersachs et al, 2010).”
BackgroundAndexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
Carpenter, E. M. L., Singh, D., Dietrich, E. A., & Gums, J. G. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098619888133 · Cited by 43
Jiménez, D., Lobo, J. L., Monréal, M., Otero, R., & Yusen, R. D. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0709-7 · Cited by 43
Bamber, L., Muston, D., McLeod, E., Guillermin, A., Lowin, J., & Patel, R. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0051-3 · Cited by 42
Sobieraj, D. M., Coleman, C. I., Pasupuleti, V., Deshpande, A., Kaw, R., & Hernandez, A. V. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.032 · Cited by 42
Seaman, C. D., Smith, K. J., & Ragni, M. V. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.09.015 · Cited by 44
“We chose this age because the mean age in clinical trials evaluating rivaroxaban and VTE was 55 to 60 years [3,4].”
BackgroundMethodInfluentialManaging pulmonary embolism from presentation to extended treatment
Cohen, A. T., Dobromirski, M., & Gurwith, M. M. P. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.09.040 · Cited by 49
Novel Oral Anticoagulants and Their Role in Clinical Practice
Wittkowsky, A. K. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.1175 · Cited by 46
Gosselin, R. C., Funk, D. M. A., Taylor, J., Francart, S. J., Hawes, E. M., Friedman, K. D., & Moll, S. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0750-oa · Cited by 43
Wu, C. M., Alotaibi, G., AlSaleh, K. A., Linkins, L., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.033 · Cited by 43
“EINSTEIN-Ext [12] Rivaroxaban 20 mg Placebo 6–12 1196 58% 58 ± 16 Recurrent VTE 1.”
BackgroundResultInfluentialBertoletti, L., Ollier, É., Duvillard, C., Delavenne, X., Beyens, M., Magalhaes, É. D., Bellet, F., Basset, T., Mismetti, P., & Laporte, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.023 · Cited by 47
Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice
Camm, A. J., Coleman, C. I., Tamayo, C., & Beyer‐Westendorf, J. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-06-0485 · Cited by 42
Couturaud, F., Pernod, G., Presles, É., Duhamel, E., Jégo, P., Provost, K., Pan‐Petesch, B., Sollier, C. B. D., Tromeur, C., Hoffmann, C., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.210971 · Cited by 47
“Whether direct oral anticoagulants, at full or low dose, 10-12 could constitute an effective and safe alternative to warfarin or could be tailored according to patients’ risk factors (including elevated D-dimer levels), 27 will need further investigation.”
BackgroundYamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.08.2206 · Cited by 43
Semmler, G., Lindorfer, A., Schaefer, B., Bartl, S., Hametner‐Schreil, S., Gensluckner, S., Balcar, L., Pomej, K., Lampichler, K., Trauner, M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.024 · Cited by 42
Duran, A. A., Sengupta, N., Diamantopoulos, A., Forster, F., Kwong, L. M., & Lees, M. (2011) · PharmacoEconomics · doi:10.2165/11599370-000000000-00000 · Cited by 43
New anticoagulants – promising and failed developments
Harenberg, J., Marx, S., Krejczy, M., & Wehling, M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01578.x · Cited by 41
“The limitations for the use of VKAs lead to an estimated underuse in up to 50% of patients requiring an effective anticoagulation (Tulner et al., 2010).”
BackgroundSista, A. K., Vedantham, S., Kaufman, J. A., & Madoff, D. C. (2015) · Radiology · doi:10.1148/radiol.2015132603 · Cited by 44
Diagnosis and management of pulmonary embolism in the elderly
Robert‐Ebadi, H., & Righini, M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.009 · Cited by 43
van Montfoort, M. L., & Meijers, J. C. M. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-11-0803 · Cited by 41
Arachchillage, D. J., Reynolds, R., Devey, T., Maclean, R., Kitchen, S., & Veen, J. V. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.09.010 · Cited by 41
Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
Turpie, A. G. G., Purdham, D. M., & Ciaccia, A. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717714921 · Cited by 44
Lensing, A. W. A., Male, C., Young, G. A., Kubitza, D., Kenet, G., Massicotte, M. P., Chan, A. K. C., Molinari, A. C., Nowak-Goettl, U., Pap, A. F., et al. (2018) · Thrombosis Journal · doi:10.1186/s12959-018-0188-y · Cited by 42
Progress in the monitoring of direct oral anticoagulant therapy
Patel, J. P., Byrne, R., Patel, R., & Arya, R. (2019) · British Journal of Haematology · doi:10.1111/bjh.15756 · Cited by 44
Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently
Gadi, I., Fatima, S., Elwakiel, A., Nazir, S., Al‐Dabet, M. M., Rana, R., Bock, F. M., Manoharan, J., Gupta, D., Biemann, R., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317219 · Cited by 42
Effective diagnosis and treatment of pulmonary embolism: Improving patient outcomes
Meyer, G. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.05.006 · Cited by 48
Advances in the Diagnosis and Treatment of Acute Pulmonary Embolism
Tapson, V. F. (2012) · F1000 Medicine Reports · doi:10.3410/m4-9 · Cited by 44
How I treat recurrent deep-vein thrombosis
Kyrle, P. A. (2015) · Blood · doi:10.1182/blood-2015-09-671297 · Cited by 42
Alexander, P., Visagan, S., Issa, R., Gorantla, V. R., & Thomas, S. (2021) · Cureus · doi:10.7759/cureus.18992 · Cited by 46
Fang, M. C., Reynolds, K., Fan, D., Prasad, P. A., Sung, S. H., Portugal, C., Garcia, E. A., & Go, A. S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28033 · Cited by 49
New oral anticoagulants: A view from the laboratory
Weitz, J. I. (2012) · American Journal of Hematology · doi:10.1002/ajh.23139 · Cited by 40
“Lessons from Clinical Trials The new oral anticoagulants have been compared with warfarin for stroke prevention in atrial fibrillation [2–4] and for treatment of venous thromboembolism [10,11].”
Direct Oral Anticoagulants—Pharmacology, Drug Interactions, and Side Effects
Dempfle, C.-E. H. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.005 · Cited by 43
Mar, P. L., Familtsev, D., Ezekowitz, M. D., Lakkireddy, D., & Gopinathannair, R. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.035 · Cited by 43
Gerotziafas, G., Mahé, I., & Elalamy, I. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s49063 · Cited by 47
New anticoagulants for the treatment of venous thromboembolism
Fernandes, C. J. C. D. S., Alves, J. L., Gavilanes, F., Prada, L. F., Morinaga, L. T. K., & Souza, R. (2016) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562016042020068 · Cited by 70
Popular naturally occurring antioxidants as potential anticoagulant drugs
Bijak, M., Saluk, J., Szelenberger, R., & Nowak, P. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.07.022 · Cited by 45
Kirkilesis, G. I., Kakkos, S. K., & Tsolakis, I. A. (2019) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2018.11.004 · Cited by 44
Haas, S. K., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Turpie, A. G. G., Goto, S., Angchaisuksiri, P., Nielsen, J. D., Kayani, G., Zaghdoun, A., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14548 · Cited by 41
Guo, W., Chen, X., Tian, X., & Li, L. (2019) · Clinical Epidemiology · doi:10.2147/clep.s219335 · Cited by 41
Use of direct oral anticoagulants in daily practice.
Almarshad, F., Alaklabi, A. A., Bakhsh, E., Pathan, A. R., & Almegren, M. (2018) · Europe PMC (PubMed Central) · Cited by 50
Ito, Y., Maejima, Y., Nakagama, S., Shiheido‐Watanabe, Y., Tamura, N., & Sasano, T. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.09.010 · Cited by 42
Rivaroxaban: An Oral Factor Xa Inhibitor
Thomas, T. F., Ganetsky, V. S., & Spinler, S. A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.12.005 · Cited by 44
Direct thrombin inhibitors in cardiovascular disease
Arsenault, K. A., Hirsh, J., Whitlock, R. P., & Eikelboom, J. W. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.61 · Cited by 40
Bleker, S. M., van Es, N., van Gils, L., Daams, J. G., Kleinjan, A., Buller, H. R., & Nisio, M. D. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30104-9 · Cited by 45
Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review
Sunkara, T., Ofori, E., Zarubin, V., Caughey, M. E., Gaduputi, V. V., & Reddy, M. (2016) · Health Services Insights · doi:10.4137/hsi.s40701 · Cited by 41
Kumano, O., Akatsuchi, K., & Amiral, J. (2021) · Biomedicines · doi:10.3390/biomedicines9030264 · Cited by 45
Anticoagulant use in older persons at risk for falls: therapeutic dilemmas—a clinical review
Mitchell, A., Elmasry, Y. E. T., van Poelgeest, E. P., & Welsh, T. J. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00811-z · Cited by 43
Diagnosis and treatment of cerebral venous thrombosis
Weimar, C., Masuhr, F., & Hajjar, K. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.126 · Cited by 39
Rivaroxaban for the treatment of venous thromboembolism
Aujesky, D., Beer, J. H., Mazzolai, L., Baldi, T., Banyai, M., Hayoz, D., Kaeslin, T., Korte, W. C., Escher, R., Husmann, M. J. W., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0209 · Cited by 42
Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban
Yang, H., Kim, S., & Song, M. J. (2016) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.0016 · Cited by 40
Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures
Deutsch, D., Boustière, C., Ferrari, É., Albaladejo, P., Morange, P., & Benamouzig, R. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17702092 · Cited by 41
Drug interactions with new oral anticoagulants in elderly patients
Stöllberger, C. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1370369 · Cited by 47
Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban
Houghton, D. E., Casanegra, A. I., Peterson, L. G., Cochuyt, J. J., Hodge, D. O., Vlazny, D. T., McBane, R. D., Froehling, D. A., & Wysokiński, W. E. (2020) · American Journal of Hematology · doi:10.1002/ajh.25820 · Cited by 39
A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant
Wadsworth, D. C., Sullivan, E., Jacky, T., Sprague, T., Feinman, H., & Kim, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13343 · Cited by 42
Kubitza, D., Becka, M., Mück, W. M., & Schwers, S. (2012) · Pharmaceuticals · doi:10.3390/ph5030279 · Cited by 39
Potential antidotes for reversal of old and new oral anticoagulants
Suryanarayan, D., & Schulman, S. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50026-6 · Cited by 42
“It was noninferior to warfarin in patients with atrial fibrillation [21] and for acute and extended management of VTE [22,23].”
BackgroundA New Generation of Oral Direct Anticoagulants
Soff, G. A. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.242834 · Cited by 46
Sindet‐Pedersen, C., Pallisgaard, J. L., Stærk, L., Gerds, T. A., Fosbøl, E. L., Torp-Pedersen, C. T., Gislason, G., & Olesen, J. B. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0745 · Cited by 43
How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther, M. A., & Cuker, A. C. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0197 · Cited by 43
Djulbegović, B., Hozo, I., Mayrhofer, T., den Ende, J. V., & Guyatt, G. H. (2018) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13091 · Cited by 40
Liu, J., Nishida, M., Inui, H., Chang, J., Zhu, Y., Kanno, K., Matsuda, H., Sairyo, M., Okada, T., Nakaoka, H., et al. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48405 · Cited by 40
Alhousani, M. M., Malik, S. U., Abu-Hashyeh, A., Poznanski, N. J., Al-Hasan, S., Roth, D. F., Alsharedi, M. F., & Mustafa, B. O. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.036 · Cited by 40
Cohen, A. T., Sah, J., Lee, T. T. H., Rosenblatt, L. C., Hlavacek, P., Emir, B., Keshishian, A. V., Yüce, H., & Luo, X. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020200 · Cited by 42
Berkman, S. A., & Song, S. S. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211002274 · Cited by 44
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.
Wang, K.-L., Chu, P. H., Lee, C., Pai, P. Y., Lin, P.-Y., Shyu, K. G., Chang, W., Chiu, K., Huang, C.-L., Lee, C. Y., et al. (2016) · Europe PMC (PubMed Central) · doi:10.6515/acs20151228a · Cited by 49
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A., & Vargas, E. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50543 · Cited by 43
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications
Barrios, V., & Escobar, C. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.172 · Cited by 40
Metadata
- Authors
- The EINSTEIN Investigators
- Corresponding author
- The EINSTEIN Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2499-2510
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115787552
- Cited by
- 3,237
- References
- 19
- Citations by year
- 2026: 90 · 2025: 105 · 2024: 118 · 2023: 153 · 2022: 169 · 2021: 189 · 2020: 261 · 2019: 242 · 2018: 248 · 2017: 232 · 2016: 300 · 2015: 267 · 2014: 290 · 2013: 255 · 2012: 188
- FWCI
- 148.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- ORBi (University of Liège) (acceptedVersion, other-oa)
- Murdoch University Research Portal (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, oral factor Xa inhibitors, venous thromboembolism, deep vein thrombosis, continuation treatment, recurrent venous thromboembolism, enoxaparin, vitamin K antagonists, warfarin, acenocoumarol, major bleeding, non-inferiority
- MeSH terms
- Rivaroxaban, Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Vitamin K, Warfarin, Enoxaparin, Venous Thrombosis, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.